Endometriosis and Microvascular Dysfunction: Role of Inflammation (Endo3/SA2)

• ClinicalTrials.gov Identifier: NCT05069740
• Recruitment Status: Recruiting
• First Posted: October 6, 2021
• Last Update Posted: December 14, 2022
• Sponsor: Penn State University
• Information provided by (Responsible Party): Lacy Alexander, Penn State University

Study Description

Brief Summary:

The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction.

Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.

Condition or disease	Intervention/treatment	Phase
Endometriosis	Drug: Salsalate Pill; Drug: Placebo	Early Phase 1

Detailed Description:

Endometriosis is an estrogen-dependent gynecological disorder associated with considerable chronic pelvic pain, pain during intercourse, and is a major cause of infertility. This disorder affects 6% - 10% of reproductive age women and can be as high as 35-50% in women experiencing pain or infertility. Endometriosis derives from the presence of endometrium-like tissue in sites outside the uterine cavity. While endometriosis is a local inflammatory syndrome, the inflammatory process is systemic.

Endometriosis is associated with higher risk of hypercholesterolemia and hypertension 8. Epidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk.

Endometriosis a disease of inflammation and increased systemic inflammatory cytokine production, although the precise mechanisms by which localized lesion results in systemic inflammation are incompletely understood. Published data confirm an elevation of several inflammatory cytokines in the circulation of women with endometriosis. Alterations in circulating miRNAs specific to endometriosis are one mechanism causing immune dysfunction and subsequent increased cytokine expression in areas remote from the endometriotic lesions. This aberrant increase in systemic cytokine production is a highly plausible putative link to accelerated vascular dysfunction and atherosclerosis in women with endometriosis.

The circulating factors LDL and oxidized LDL are two of the many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 is a ubiquitously expressed scavenger receptor, stimulated by oxLDL, Ang II, and other inflammatory cytokines, and inhibited by estrogen. LOX-1 is the upstream signaling initiator of mechanisms including increased oxidant production, reduced nitric oxide (NO) metabolism, and impaired intracellular trafficking. Thus, LOX-1 signal transduction functionally results in pronounced endothelial dysfunction.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 24 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: This is a single blind placebo controled cross over study. Two groups of women complete this study: 1) healthy women between the ages of 18 and 45 years (Controls); 2) women between the ages of 18 and 45 years with endometriosis. Once consented and screening, each subject is randomized to either 5 days of salsalate or placebo. On day 5, each subject participates in a cutaneous microdialysis (MD) and flow mediated dilation (FMD) experiment. After a 2-week washout, the participant returns to repeat the study with the other oral drug (salsalate/placebo). These treatments are blinded to only the investigators. The participants and nurse on staff knows which treatment the subject is taking if there are any questions or safety concerns.
• Masking: Single (Investigator)
• Masking Description: These treatments/placebo are blinded to the investigators. The subjects, physician, and the nurse on staff knows which treatment the subject is taking if there are any questions or safety concerns.
• Primary Purpose: Basic Science
• Official Title: Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Endometriosis
• Actual Study Start Date: January 1, 2022
• Estimated Primary Completion Date: December 31, 2025
• Estimated Study Completion Date: December 31, 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Salsalate; 3000 mg/day salsalate (1500 mg twice daily) for 5 days	Drug: Salsalate Pill; Salsalate acts as an NFkB inhibitor to reduce systemic inflammation
Placebo Comparator: Placebo; 1 capsule contain microcrystalline cellulose filler (twice daily) for 5 days	Drug: Placebo; Placebo for the salsalate intervention

Outcome Measures

Primary Outcome Measures :

1. cutaneous vascular conductance [ Time Frame: 5 days after treatment ]
   doppler flowmetry used to measure cutaneous vascular conductance (cvc = red cell flux/mean arterial pressure) to assess microvascular endothelial function
2. brachial artery diameter and blood flow velocity [ Time Frame: 5 days after treatment ]
   continuous ultrasound imaging measurements of brachial artery diameter and blood flow velocity to assess endothelial function
3. Sera LOX-1 protein expression [ Time Frame: 5 days after treatment ]
   Peripheral Blood Mononuclear Cell Isolation, LOX-1 expression quantified using real time pCR
4. Biopsy LOX-1 protein expression [ Time Frame: 5 days after treatment ]
   Bio-Rad DC assay, western blot technique used for LOX-1 protein receptor expression

Secondary Outcome Measures :

1. sera reproductive hormone analysis [ Time Frame: 5 days after treatment ]
   analysis of plasma estradiol, progesterone, and sex hormone binding globulin determined through hormone assay
2. sera cytokine expression analysis [ Time Frame: 5 days after treatment ]
   expression of cytokines CRP, TNF-a, IL-1B, IL-6, IL-8 determined through multiplex assay
3. skin biopsy biochemical analysis [ Time Frame: 5 days after treatment ]
   the expression of estrogen receptor alpha and beta, the protein pVASP/VASP, and the enzyme peNOS/eNOS is determined using Bio-Rad DC assay, western blot technique

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 45 Years (Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Healthy women between the ages of 18 and 45 years (Controls), taking oral contraceptive or with regular menses every 26-34 days
• Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician <5 years prior, and reported by the subject to the researchers)
• Tylenol if the subject has acute pain is allowed
• Contraceptive use is allowed

Exclusion Criteria:

• Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)
• Diabetes (HbA1C 6.5%)
• BP>140/90
• Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)
• Pregnancy
• Breastfeeding
• Taking illicit and/or recreational drugs
• Abnormal liver function
• Rash, skin disease, disorders of pigmentation, known skin allergies
• Diagnosed or suspected metabolic or cardiovascular disease
• Persistent unexplained elevations of serum transaminases
• Known allergy to latex or investigative substances (including salsalate or simvastatin)
• History of gastrointestinal bleeding

Contacts and Locations

Contacts

Contact: Lacy M Alexander, Ph.D.; 8148671781; lma191@psu.edu

Contact: Susan Slimak, RN; 814-863-8554; sks31@psu.edu

Locations

United States, Pennsylvania

The Pennsylvania State University; Recruiting

University Park, Pennsylvania, United States, 16801

Contact: Lacy M Alexander, PhD 814-867-1781 lma191@psu.edu

Sponsors and Collaborators

Penn State University

More Information

• Responsible Party: Lacy Alexander, Professor of Kinesiology, Penn State University
• ClinicalTrials.gov Identifier: NCT05069740
• Other Study ID Numbers: 18369
• First Posted: October 6, 2021
• Last Update Posted: December 14, 2022
• Last Verified: December 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Lacy Alexander, Penn State University:

skin blood flow; inflammation; Lectin-like oxidized LDL receptor (LOX-1); intradermal microdialysis

Additional relevant MeSH terms:

Endometriosis; Salicylsalicylic acid; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Analgesics; Sensory System Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Anti-Inflammatory Agents; Antirheumatic Agents